Year: 2023

  • IMMUPHARMA AT BIO-EUROPE SPRING 2024. 18-20 March 2024 | Barcelona

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Europe Spring. The event will be held between 18-20 March 2024, in Barcelona. BIO-Europe Spring is the premier springtime partnering event, designed to provide biotechnology companies with the opportunity to present to…

  • Financial, Business and Portfolio Development Update

    ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce a positive and comprehensive financial, business and portfolio development update. This follows on from our announcement on 19 December 2023, where we provided a detailed update on our late stage P140 (Lupuzor™) program, in patients with systemic lupus erythematosus…

  • Proactive

    Proactive – ImmuPharma discusses financial stability and promising drug developments 6 March 2024 ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments – 6 March 2024

  • TR1 – Major Holding by Lanstead (Date: 28 December 2023)

    To view the form of notification click here

  • TR1 – Major holding by Lanstead

    To view click here

  • Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA

    ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce key updates on its late stage P140 (Lupuzor™) program, in patients with systemic lupus erythematosus (“SLE/Lupus”). Highlights Simbec-Orion has been appointed as the Contract Research Organisation (“CRO”), for the P140 (Lupuzor™) Phase 3 study in SLE, following extensive due-diligence…

  • Incanthera Secures Commercial Skincare Deal & £1M Fundraise

    ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc (“Incanthera”), the dermatology and oncology specialist, in which ImmuPharma currently holds a 12.7% shareholding. Within the announcement, Incanthera announces a significant commercial skincare deal with Marionnaud (part of the A.S. Watson…

  • Zak Mir – Tim McCarthy

    Zak Mir – Tim McCarthy, CEO Immupharma 22 September 2023 Zak Mir talks to Tim McCarthy, Chairman and CEO, Immupharma, about the recent fund raise, highlights of the company’s portfolio, and the main focus of its drug discovery and development strategy – 22 September 2023

  • Major shareholding by Lanstead via TR1

    To view notification form click here

  • Result of retail offer and Director shareholding

    ImmuPharma Plc is pleased to announce that further to the Company’s announcement at 7:02 a.m. on 31 August 2023, the Company has conditionally raised gross proceeds of £130,683 through the issue of 6,534,150 New Ordinary Shares at a price of 2 pence to existing retail investors of the Company, via the Winterflood Retail Access Platform (“WRAP”), in addition…